Sep 12th 2012 - Edison Investment Research today published a report on Vectura (VEC.L, LSE:VEC, LON:VEC) entitled "Compelling Data At ERS". In summary, the report says:
Three key regulatory events coupled with milestones from Novartis are expected in H212: the EU and Japan approvals of NVA237 and the QVA149 European MAA filing. Data presentations at the European Respiratory Society (ERS) meeting provided further compelling data on the clinical profiles of these drugs. Detailed Phase III data for QVA149 showed superior lung function against all comparators, including its constituents (indacaterol and NVA237), current gold standard COPD therapies (Spiriva and Advair) and placebo. The closest LAMA/LABA competitor, GSK/Theravance’s UMEC/VI, fared less well, with dose ranging data that might raise FDA questions.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »